Phase 2 study of prolonged administration of oral etoposide in combination with weekly cisplatin in advanced non-small cell lung cancer

F. Robert, R. H. Wheeler, D. Molthrop, A. Bailey, S. Chen

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

We administered chemotherapy consisting of a 21-day course of oral etoposide (50 mg/m2/day) and a 3-weekly dose of cisplatin (30-33 mg/m2/week) to 23 chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC). Six patients achieved a partial response (28.6%; 95% confidence interval, 11.3-52.2%), with a median response duration of 4 months and a median overall survival of 5 months. Besides alopecia, myelosuppression was the most significant drug-related toxicity. Observed side effects in 59 cycles of chemotherapy were granulocytopenia (<1,000/μl) in 23% of the treatment cycles, thrombocytopenia (<75,000/μl) in 25%, anemia (<10 g/dl) in 64%, and nausea-vomiting (grades ≥2) in 8%. Mild renal insufficiency (serum creatinine, 1.5-2.1 mg/dl) occurred in six patients. Three toxic deaths were observed during or immediately after cycle 1, and were related to granulocytopenia. We conclude that this regimen has modest activity in advanced NSCLC; but this therapeutic approach does not appear to produce a major improvement in the treatment of this disease. Thus, in advanced NSCLC, continued evaluation of new chemotherapeutic agents should remain the major emphasis of investigational therapy.

Original languageEnglish
Pages (from-to)383-386
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume17
Issue number5
DOIs
StatePublished - 1 Jan 1994

Fingerprint Dive into the research topics of 'Phase 2 study of prolonged administration of oral etoposide in combination with weekly cisplatin in advanced non-small cell lung cancer'. Together they form a unique fingerprint.

  • Cite this